logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
T

Toshio Shimizu

department of medical oncology
H指数:42
被引数:8,784

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world multicenter study of immune checkpoint inhibitors in advanced cervical cancer across HPV-associated and HPV-independent subtypes

真实世界中免疫检查点抑制剂在HPV相关和HPV非相关亚型晚期宫颈癌中的多中心研究

International Journal of Clinical Oncology
IF2.8
2025-11-260
PRE
Kazuhiro Ko; Mayu Fukuda; Koji Yamanoi; Nobutaka Hayashi; Hisateru Yasui; Takuma Hayashi; Yoshihiro Yakushijin; Takehiko Tsumura; Atsushi Shirakawa; Chiho Nakashima; Yoshinori Imamura; Chikako Yamauchi; Toshio Shimizu; Takahito Ashihara; Nobuhiro Shibata; Takeshi Kotake; Aya Toyofuku; Taito Miyamoto; Rin Mizuno; Mana Taki; Ryusuke Murakami; Satoshi Morita; Manabu Muto; Masaki Mandai
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors (vol 14, 1376551, 2024)
FRONTIERS IN ONCOLOGY
IF3.3
2025-01-310
OAAI
Shimizu, Toshio; Powderly, John; Abdul Razak, Albiruni; Lorusso, Patricia; Miller, Kathy D.; Kao, Steven; Kongpachith, Sarah; Tribouley, Catherine; Graham, Michelle; Stoll, Brian; Patel, Maulik; Sahtout, Mohammad; Blaney, Martha; Leibman, Rachel; Golan, Talia; Tolcher, Anthony
First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors
FRONTIERS IN ONCOLOGY
IF3.3
2024-10-291
OAAI
Shimizu, Toshio; Powderly, John; Abdul Razak, Albiruni; Lorusso, Patricia; Miller, Kathy D.; Kao, Steven; Kongpachith, Sarah; Tribouley, Catherine; Graham, Michelle; Stoll, Brian; Patel, Maulik; Sahtout, Mohammad; Blaney, Martha; Leibman, Rachel; Golan, Talia; Tolcher, Anthony
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan

与datopotamab deruxtecan相关的特别关注的不良事件的临床管理，监测和预防

CANCER TREATMENT REVIEWS
IF10.5
2024-04-016
OAAI
Heist, Rebecca S.; Sands, Jacob; Bardia, Aditya; Shimizu, Toshio; Lisberg, Aaron; Krop, Ian; Yamamoto, Noboru; Kogawa, Takahiro; Al-Hashimi, Saba; Fung, Simon S. M.; Galor, Anat; Pisetzky, Francesca; Basak, Priyanka; Lau, Cindy; Meric-Bernstam, Funda
Phase I biomarker analysis of farletuzumab ecteribulin (FZEC), formerly MORAb-202, effects on cancer responses in patients with platinum resistant ovarian cance
MOLECULAR CANCER THERAPEUTICS
IF5.5
2023-12-010
PRE
Zhang, Yan; Zimmermann, Bob; Li, Shuyu; Uenaka, Toshimitsu; Furuuchi, Keiji; Yonemori, Kan; Shimizu, Toshio; Nishio, Shin; Yunokawa, Mayu; Matsumoto, Koji; Takehara, Kazuhiro; Hasegawa, Kosei; Hirashima, Yasuyuki; Kato, Hidenori; Otake, Yohei; Miura, Takuma; Matsui, Junji; Li, Meijuan
Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group

亚太地区转移性癌症患者使用下一代测序的建议: 来自APODDC工作组的报告

ESMO OPEN
IF8.3
2023-08-0117
OAAI
Loong, H. H.; Shimizu, T.; Prawira, A.; Tan, A. C.; Tran, B.; Day, D.; Tan, D. S. P.; Ting, F. I. L.; Chiu, J. W.; Hui, M.; Wilson, M. K.; Prasongsook, N.; Koyama, T.; Reungwetwattana, T.; Tan, T. J.; Heong, V.; Voon, P. J.; Park, S.; Tan, I. B.; Chan, S. L.; Tan, D. S. W.
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
CANCER DISCOVERY
IF33.3
2023-06-2714
OA
Koyama, Takafumi; Shimizu, Toshio; Kojima, Yuki; Sudo, Kazuki; Okuma, Hitomi Sumiyoshi; Shimoi, Tatsunori; Ichikawa, Hitoshi; Kohsaka, Shinji; Sadachi, Ryo; Hirakawa, Akihiro; Yoshida, Akihiko; Ando, Reiko Makihara; Ueno, Toshihide; Yanagaki, Mitsuru; Matsui, Naoko; Nakamura, Kenichi; Yamamoto, Noboru; Yonemori, Kan
A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
CANCER RESEARCH
IF16.6
2023-04-1420
PRE
Murciano-Goroff, Yonina R.; Heist, Rebecca S.; Kuboki, Yasutoshi; Koyama, Takafumi; Ammakkanavar, Natraj Reddy; Hollebecque, Antoine; Patnaik, Amita; Shimizu, Toshio; Spira, Alexander I.; Nagasaka, Misako; Han, Ji-Youn; Iams, Wade Thomas; Deming, Dustin; Call, Justin; Cassier, Philippe; Han, Sae-Won; Chu, Quincy Siu-Chung; Cosman, Rasha; Durm, Gregory; Burns, Timothy; Willard, Melinda D.; Liu, Shiyao; Callies, Sophie; Balar, Arjun V.; Sabari, Joshua K.
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
CLINICAL CANCER RESEARCH
IF10.2
2022-10-2588
OA
Meric-Bernstam, Funda; Sweis, Randy F.; Kasper, Stefan; Hamid, Omid; Bhatia, Shailender; Dummer, Reinhard; Stradella, Agostina; Long, Georgina, V; Spreafico, Anna; Shimizu, Toshio; Steeghs, Neeltje; Luke, Jason J.; McWhirter, Sarah M.; Mueller, Thomas; Nair, Nitya; Lewis, Nancy; Chen, Xinhui; Bean, Andrew; Kattenhorn, Lisa; Pelletier, Marc; Sandhu, Shahneen

研究方向

暂未获取到该数据
T
Takafumi Koyama
H 指数:25论文数:473被引数:2,030
K
Kan Yonemori
H 指数:48论文数:1,048被引数:1.0万
N
Noboru Yamamoto
H 指数:0论文数:9被引数:0
N
Noboru Yamamoto
H 指数:66论文数:1,329被引数:1.7万
S
Shunsuke Kondo
H 指数:48论文数:903被引数:1.0万
K
Kazuhiko Nakagawa
H 指数:103论文数:1,451被引数:6.1万
F
Funda Meric‐Bernstam
H 指数:146论文数:2,622被引数:10.5万
A
Alexander I. Spira
H 指数:67论文数:943被引数:2.8万
K
Kazuki Sudo
H 指数:29论文数:491被引数:3,004
A
Aaron Lisberg
H 指数:27论文数:197被引数:9,727